Venous Thromboembolism

Pharmacor -- September 2006

  Introduction:

The high-profile withdrawal of ximelagatran, AstraZeneca’s first-to-market oral direct thrombin inhibitor (DTI), has left the venous thromboembolism (VTE) market wide open to therapies that address its defining unmet need for a safe and consistently effective oral anticoagulant.

  Questions Answered in This Report:

Awareness of the risk of VTE after surgery is increasing. How will this awareness affect the prescription of anticoagulants in the surgical population?

By 2010, agents in two novel classes - the oral DTIs and the oral direct factor Xa inhibitors - will be licensed for both the treatment and prophylaxis of VTE. How will these agents affect the prescription of existing anticoagulants? What will the dynamics be in both the treatment and prophylaxis markets?

The patents of several market-leading agents, including enoxaparin (Sanofi-Aventis’s Lovenox/Clexane) and fondaparinux (GlaxoSmithKline’s Arixtra), recently expired or will expire soon. How will these expiries affect market value and prescription of these agents?

In  VTE prophylaxis, care pathways are often fragmented and pharmacological prophylaxis is often inadequate. How do the attitudes of the major medical specialties involved in the treatment and prophylaxis of VTE differ?

  Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 43 country-specific interviews with thought leaders in cardiology, hematology, angiology, orthopedic surgery, and internal medicine.

Epidemiology: Incidence of DVT, PE, and recurrent DVT/PE; populations eligible for prophylaxis in major orthopedic surgery, high-risk general surgery, vascular surgery, neurosurgery, trauma, and cancer.

Population segments in market forecast: DVT, PE, and recurrent DVT/PE; major orthopedic surgery, high-risk general surgery, vascular surgery, neurosurgery, trauma, and cancer.

Emerging therapies: Phase II, 10 drugs; Phase III, 6 drugs. Coverage of 7 select preclinical and Phase I products.

Market forecast features: An estimation of the size of the surgical VTE prophylaxis market.